MS
KLRS

Maven Securities’s Kalaris Therapeutics KLRS Stock Holding History

Maven Securities’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-31,981
Closed -$2.5M – 1242
2023
Q2 		$2.5M Buy
+31,981
New +$3.04M 0.04% 243
2021
Q1 		– Sell
-865
Closed -$799K – 1320
2020
Q4 		$799K Buy
+865
New +$665K 0.08% 282

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities's KLRS Position: Q3 2023 in Review

Maven Securities sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 31,981 shares — an estimated $2.5M sold.

Maven Securities first reported a position in KLRS in Q4 2020 and held it in 2 quarters. The position peaked at $2.5M in Q2 2023. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

  • Maven Securities reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Maven Securities sold 31,981 Kalaris Therapeutics shares in Q3 2023, an estimated $2.5M.
  • Maven Securities first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Kalaris Therapeutics position peaked at $2.5M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Maven Securities's 13F filing for Q3 2023, filed 13 Nov 2023.